Ep. 301: “Cell Fate Decisions in Cancer” Featuring Dr. Mark Hatley
Dr. Mark Hatley is an Associate Faculty Member and Director of the Division of Molecular Oncology at St. Jude Children's Research Hospital. His research focuses on the developmental origins and genetic mechanisms of pediatric rhabdomyosarcoma. He talks about his work on pediatric oncology and the mechanisms that differentiate normal development from cancer. He also discusses the role of PAX3-FOXO1 and DICER1 in tumorigenesis.
--------
1:19:50
--------
1:19:50
Ep. 300: “Autologous Cell Therapy” Featuring Dr. Jeanne Loring
Dr. Jeanne Loring is a Co-Founder of Aspen Neuroscience and Professor Emeritus at Scripps Research. She talks about generating gametes from the functionally extinct northern white rhinoceros, Aspen's early days and its recent clinical trial results for Parkinson's cell therapy, and sending her own stem cells into space. She also discusses the need for genetic variation in iPSC lines.
--------
1:35:10
--------
1:35:10
Ep. 299: “Spinal Cord Development” Featuring Dr. James Briscoe
Dr. James Briscoe is a Group Leader at the Francis Crick Institute and Editor-In-Chief of Development. His lab uses an interdisciplinary approach, including mice, chicks, and other models, to study developmental dynamics. He discusses his lab's work on human trunk formation and his role as an Editor-In-Chief.
--------
1:23:20
--------
1:23:20
Ep. 298: “ISSCR 2025: On the Ground”
In June 2025, we attended ISSCR 2025, the annual meeting of the International Society for Stem Cell Research, in Hong Kong. We spoke with delegates about their research, their impressions of the meeting, and the most memorable research presented. They also discussed their experiences exploring Hong Kong.
--------
59:07
--------
59:07
Ep. 297: “Live at ISSCR 2025: Advancing Regenerative Medicine with CiPSCs” Featuring Drs. Hongkui Deng and Candice Liew
Dr. Hongkui Deng is the Director of the Institute of Stem Cell Research at Peking University and Dr. Candice Liew is a Senior Scientist at Reprogenix Bioscience. In this special episode recorded in front of a live audience at ISSCR 2025 in Hong Kong, they discuss their groundbreaking study transplanting CiPSC-derived islets into a patient with type 1 diabetes. They talk about their approach to chemical reprogramming, immune tolerance, and the therapy's impact on the first patient.
Colombia